JP2012509886A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509886A5
JP2012509886A5 JP2011537606A JP2011537606A JP2012509886A5 JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5 JP 2011537606 A JP2011537606 A JP 2011537606A JP 2011537606 A JP2011537606 A JP 2011537606A JP 2012509886 A5 JP2012509886 A5 JP 2012509886A5
Authority
JP
Japan
Prior art keywords
tcl1
activator protein
promotes
pharmaceutical composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537606A
Other languages
English (en)
Other versions
JP2012509886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065072 external-priority patent/WO2010059779A1/en
Publication of JP2012509886A publication Critical patent/JP2012509886A/ja
Publication of JP2012509886A5 publication Critical patent/JP2012509886A5/ja
Pending legal-status Critical Current

Links

Claims (7)

  1. Tcl1上のエピトープに結合する抗体であって、当該抗体は、当該エピトープとアクチベータータンパク質1(AP−1)の間の相互作用、の少なくとも1つを調節する、前記抗体。
  2. 請求項1に記載の抗体を含む、医薬組成物。
  3. 哺乳動物においてアクチベータータンパク質1(AP−1)の活性が改変される、B−CLL疾患状態を治療するための医薬組成物であって、Tcl1タンパク質上のエピトープに結合可能な抗体を含み、ここで当該抗体はTcl1が増進するアクチベータータンパク質1(AP−1)の活性を調節する、前記医薬組成物。
  4. 哺乳動物においてアクチベータータンパク質1(AP−1)の活性が改変される、B−CLL疾患状態を治療するための医薬組成物であって、アクチベータータンパク質1(AP−1)のペプチド断片を含み、ここで当該ペプチド断片は、アクチベータータンパク質1(AP−1)に結合し、そして、Tcl1が増進するアクチベータータンパク質1(AP−1)のキナーゼ活性を調節する、前記医薬組成物。
  5. Tcl1模倣体を含む化合物であって、当該Tcl1模倣体は、いかなる細胞においてもアクチベータータンパク質1(AP−1)に結合し、そしてTcl1が増進するアクチベータータンパク質1(AP−1)の活性化を模倣するのに機能的に活性である、前記化合物。
  6. 哺乳動物においてアクチベータータンパク質1(AP−1)の活性が改変される、B−CLL疾患状態を治療するための医薬組成物であって、Tcl1模倣体を含み、ここで当該Tcl1模倣体は、アクチベータータンパク質1(AP−1)に結合し、そして、Tcl1が増進するアクチベータータンパク質1(AP−1)のキナーゼ活性を活性化する、前記医薬組成物。
  7. Tcl1アンタゴニストを含む化合物であって、ここで当該Tcl1アンタゴニストは、いかなる細胞においてもアクチベータータンパク質1(AP−1)に結合し、そしてTcl1が増進するアクチベータータンパク質1(AP−1)の活性化を調節するのに機能的に活性である、前記化合物。
JP2011537606A 2008-11-21 2009-11-19 転写制御因子としてのTcl1 Pending JP2012509886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (2)

Publication Number Publication Date
JP2012509886A JP2012509886A (ja) 2012-04-26
JP2012509886A5 true JP2012509886A5 (ja) 2012-06-07

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537606A Pending JP2012509886A (ja) 2008-11-21 2009-11-19 転写制御因子としてのTcl1

Country Status (7)

Country Link
US (1) US20110311555A1 (ja)
EP (1) EP2352524A1 (ja)
JP (1) JP2012509886A (ja)
CN (1) CN102271706A (ja)
AU (1) AU2009316584A1 (ja)
CA (1) CA2744326A1 (ja)
WO (1) WO2010059779A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
ES2527592T3 (es) 2006-01-05 2015-01-27 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico del cáncer de colon
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2007227423B2 (en) 2006-03-20 2013-11-07 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
AU2007272947B2 (en) 2006-07-13 2013-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Micro-RNA-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
AU2007346101B2 (en) 2006-09-19 2013-08-15 The Ohio State University Research Foundation TCL1 expression in chronic lymphocytic leukemia (CLL) regulated by miR-29 and miR-181
CA2667617A1 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
US8465918B2 (en) 2007-08-03 2013-06-18 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHODS FOR IDENTIFYING INTERACTION OF THE "FRAGILE HISTIDINE TRIAD" GENE (FHIT) AND USES THEREOF
ES2433940T3 (es) 2008-06-11 2013-12-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia
CN102803511A (zh) 2009-11-23 2012-11-28 俄亥俄州立大学 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
WO2013110053A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
EP1507773B1 (en) * 2002-03-08 2015-09-16 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals

Similar Documents

Publication Publication Date Title
JP2012509886A5 (ja)
HRP20190312T1 (hr) Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba
EA200870265A1 (ru) Функционально активные антитела
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
UA113712C2 (xx) Антитіло до fap і способи його застосування
IL186671A (en) Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs
JP2007051159A5 (ja)
MX2012012927A (es) Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
NZ585465A (en) Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
BR112012013876A2 (pt) proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos
JP2007520566A5 (ja)
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA201700111A1 (ru) Полипептидные конструкции и их применение
JP2015500002A5 (ja)
GEP20135930B (en) ANTI-cMET ANTIBODY
IL198379A (en) Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease
BRPI0607349A2 (pt) combinação de xolair com agente imunossupressor
EA200901421A1 (ru) Антитела к il-25
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
WO2008049990A3 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.